BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs 2020;12:1703531. [PMID: 31847708 DOI: 10.1080/19420862.2019.1703531] [Cited by in Crossref: 219] [Cited by in F6Publishing: 193] [Article Influence: 219.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu T, Zhang J, Wang T, Wang X. Recombinant antibodies aggregation and overcoming strategies in CHO cells. Appl Microbiol Biotechnol 2022. [PMID: 35608667 DOI: 10.1007/s00253-022-11977-0] [Reference Citation Analysis]
2 Reiss AB, Montufar N, DeLeon J, Pinkhasov A, Gomolin IH, Glass AD, Arain HA, Stecker MM. Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans. Neurologist 2021;26:52-61. [PMID: 33646990 DOI: 10.1097/NRL.0000000000000320] [Reference Citation Analysis]
3 Verma S, Thapa S, Siddiqui N, Chakdar H. Cyanobacterial secondary metabolites towards improved commercial significance through multiomics approaches. World J Microbiol Biotechnol 2022;38:100. [PMID: 35486205 DOI: 10.1007/s11274-022-03285-6] [Reference Citation Analysis]
4 Botzanowski T, Hernandez-alba O, Malissard M, Wagner-rousset E, Deslignière E, Colas O, Haeuw J, Beck A, Cianférani S. Middle Level IM–MS and CIU Experiments for Improved Therapeutic Immunoglobulin Subclass Fingerprinting. Anal Chem 2020;92:8827-35. [DOI: 10.1021/acs.analchem.0c00293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chiba S, Tanabe A, Nakakido M, Okuno Y, Tsumoto K, Ohta M. Structure-based design and discovery of novel anti-tissue factor antibodies with cooperative double-point mutations, using interaction analysis. Sci Rep 2020;10:17590. [PMID: 33067496 DOI: 10.1038/s41598-020-74545-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Furuuchi K, Rybinski K, Fulmer J, Moriyama T, Drozdowski B, Soto A, Fernando S, Wilson K, Milinichik A, Dula ML, Tanaka K, Cheng X, Albone E, Uenaka T. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci 2021;112:2467-80. [PMID: 33756060 DOI: 10.1111/cas.14898] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs 2021;13:1860476. [PMID: 33459118 DOI: 10.1080/19420862.2020.1860476] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 35.0] [Reference Citation Analysis]
8 Jallinoja VIJ, Houghton JL. Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy. J Nucl Med 2021;62:1200-6. [PMID: 34016727 DOI: 10.2967/jnumed.120.260687] [Reference Citation Analysis]
9 Al Qaraghuli MM. Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. Front Oncol 2020;10:559596. [PMID: 33324546 DOI: 10.3389/fonc.2020.559596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Verscheure L, Vanhoenacker G, Schneider S, Merchiers T, Storms J, Sandra P, Lynen F, Sandra K. 3D-LC-MS with 2D Multimethod Option for Fully Automated Assessment of Multiple Attributes of Monoclonal Antibodies Directly from Cell Culture Supernatants. Anal Chem 2022. [PMID: 35442636 DOI: 10.1021/acs.analchem.1c05461] [Reference Citation Analysis]
11 Makowski EK, Wu L, Desai AA, Tessier PM. Highly sensitive detection of antibody nonspecific interactions using flow cytometry. MAbs 2021;13:1951426. [PMID: 34313552 DOI: 10.1080/19420862.2021.1951426] [Reference Citation Analysis]
12 Brinth AR, Svenson K, Mosyak L, Cunningham O, Hickling T, Lambert M. Crystal structure of ultra-humanized anti-pTau Fab reveals how germline substitutions humanize CDRs without loss of binding'. Sci Rep 2022;12:8699. [PMID: 35610505 DOI: 10.1038/s41598-022-12838-6] [Reference Citation Analysis]
13 Cao M, Parthemore C, Jiao Y, Korman S, Aspelund M, Hunter A, Kilby G, Chen X. Characterization and Monitoring of a Novel Light-heavy-light Chain Mispair in a Therapeutic Bispecific Antibody. J Pharm Sci 2021;110:2904-15. [PMID: 33894207 DOI: 10.1016/j.xphs.2021.04.010] [Reference Citation Analysis]
14 Georges GJ, Dengl S, Bujotzek A, Hesse F, Fischer JA, Gärtner A, Benz J, Lauer ME, Ringler P, Stahlberg H, Plath F, Brinkmann U, Imhof-jung S. The Contorsbody, an antibody format for agonism: Design, structure, and function. Computational and Structural Biotechnology Journal 2020;18:1210-20. [DOI: 10.1016/j.csbj.2020.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Lee BI, Park MH, Choi J, Shin SH, Byeon JJ, Park Y, Shin YG. Liquid chromatography-high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics. Biomed Chromatogr 2020;34:e4855. [PMID: 32304111 DOI: 10.1002/bmc.4855] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kannan A, Shieh IC, Negulescu PG, Chandran Suja V, Fuller GG. Adsorption and Aggregation of Monoclonal Antibodies at Silicone Oil-Water Interfaces. Mol Pharm 2021;18:1656-65. [PMID: 33656340 DOI: 10.1021/acs.molpharmaceut.0c01113] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Luan X, Wu Y, Shen YW, Zhang H, Zhou YD, Chen HZ, Nagle DG, Zhang WD. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat Prod Rep 2021;38:7-17. [PMID: 32776055 DOI: 10.1039/d0np00019a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hanf KJM, Arndt JW, Liu Y, Gong BJ, Rushe M, Sopko R, Massol R, Smith B, Gao Y, Dalkilic-Liddle I, Lee X, Mojta S, Shao Z, Mi S, Pepinsky RB. Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site. MAbs 2020;12:1713648. [PMID: 31928294 DOI: 10.1080/19420862.2020.1713648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Ermakov EA, Nevinsky GA, Buneva VN. Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States. Int J Mol Sci 2020;21:E5392. [PMID: 32751323 DOI: 10.3390/ijms21155392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Grazioli S, Petris G. Synthetic genomics for curing genetic diseases. Prog Mol Biol Transl Sci 2021;182:477-520. [PMID: 34175051 DOI: 10.1016/bs.pmbts.2021.02.002] [Reference Citation Analysis]
21 Huang B, Zhu L, Wei H, Shi H, Zhang D, Yuan H, Luan L, Zheng N, Xu S, Nawaz W, Hong Y, Wu X, Wu Z. Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer. Front Immunol 2021;12:678318. [PMID: 34248960 DOI: 10.3389/fimmu.2021.678318] [Reference Citation Analysis]
22 Carvalho SB, Gomes RA, Pfenninger A, Fischer M, Strotbek M, Isidro IA, Tugçu N, Gomes-Alves P. Multi attribute method implementation using a High Resolution Mass Spectrometry platform: From sample preparation to batch analysis. PLoS One 2022;17:e0262711. [PMID: 35085302 DOI: 10.1371/journal.pone.0262711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
23 Fernández-Quintero ML, Pomarici ND, Math BA, Kroell KB, Waibl F, Bujotzek A, Georges G, Liedl KR. Antibodies exhibit multiple paratope states influencing VH-VL domain orientations. Commun Biol 2020;3:589. [PMID: 33082531 DOI: 10.1038/s42003-020-01319-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
24 Fernández-quintero ML, Quoika PK, Wedl FS, Seidler CA, Kroell KB, Loeffler JR, Pomarici ND, Hoerschinger VJ, Bujotzek A, Georges G, Kettenberger H, Liedl KR. Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats. Front Mol Biosci 2022;9:812750. [DOI: 10.3389/fmolb.2022.812750] [Reference Citation Analysis]
25 Arslan FB, Ozturk Atar K, Calis S. Antibody-mediated drug delivery. Int J Pharm 2021;596:120268. [PMID: 33486037 DOI: 10.1016/j.ijpharm.2021.120268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Jung BK, Ko HY, Kang H, Hong J, Ahn HM, Na Y, Kim H, Kim JS, Yun CO. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade. J Immunother Cancer 2020;8:e000763. [PMID: 32753544 DOI: 10.1136/jitc-2020-000763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
27 White JM, Escorcia FE, Viola NT. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics 2021;11:6293-314. [PMID: 33995659 DOI: 10.7150/thno.57177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
28 Dacoba TG, Anthiya S, Berrecoso G, Fernández‐mariño I, Fernández‐varela C, Crecente‐campo J, Teijeiro‐osorio D, Torres Andón F, Alonso MJ. Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues. Adv Funct Mater 2021;31:2009860. [DOI: 10.1002/adfm.202009860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
29 Srdic-Rajic T, Metlas R. Antibody VH domain sequence analysis by a bioinformatics approach based on electronic amino acid properties may help to predict paratop location. Immunol Lett 2021:S0165-2478(21)00172-3. [PMID: 34785254 DOI: 10.1016/j.imlet.2021.11.003] [Reference Citation Analysis]
30 Zhang HN, Xue JB, Wang AZ, Jiang HW, Merugu SB, Li DW, Tao SC. EASINESS: E. coli Assisted Speedy affINity-maturation Evolution SyStem. Front Immunol 2021;12:747267. [PMID: 34925322 DOI: 10.3389/fimmu.2021.747267] [Reference Citation Analysis]
31 Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ, Abbate A, Crea F, Massetti M, Aspromonte N. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med 2020;10:277-87. [PMID: 32599589 DOI: 10.1159/000509483] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
32 Zambrano N, Froechlich G, Lazarevic D, Passariello M, Nicosia A, De Lorenzo C, Morelli MJ, Sasso E. High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand. Cancers 2022;14:1325. [DOI: 10.3390/cancers14051325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther 2021;:107917. [PMID: 34171334 DOI: 10.1016/j.pharmthera.2021.107917] [Reference Citation Analysis]
34 Domnowski M, Lo Presti K, Binder J, Reindl J, Lehmann L, Kummer F, Wolber M, Satzger M, Dehling M, Jaehrling J, Frieß W. Generation of mAb Variants with Less Attractive Self-Interaction but Preserved Target Binding by Well-Directed Mutation. Mol Pharm 2021;18:236-45. [PMID: 33331157 DOI: 10.1021/acs.molpharmaceut.0c00848] [Reference Citation Analysis]
35 Gao Y, Zhang B, Yang J. Evinacumab for the treatment of homozygous familial hypercholesterolemia. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2047934] [Reference Citation Analysis]
36 Hofmann T, Krah S, Sellmann C, Zielonka S, Doerner A. Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies. Int J Mol Sci 2020;21:E6551. [PMID: 32911608 DOI: 10.3390/ijms21186551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Chan DTY, Groves MAT. Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies. Emerg Top Life Sci 2021:ETLS20200331. [PMID: 33660765 DOI: 10.1042/ETLS20200331] [Reference Citation Analysis]
38 Trastoy B, Naegeli A, Anso I, Sjögren J, Guerin ME. Structural basis of mammalian mucin processing by the human gut O-glycopeptidase OgpA from Akkermansia muciniphila. Nat Commun 2020;11:4844. [PMID: 32973204 DOI: 10.1038/s41467-020-18696-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
39 Boniche-Alfaro C, Kischkel B, Thomaz L, Carvalho-Gomes MM, Lopes-Bezerra LM, Nosanchuk JD, Taborda CP. Antibody- Based Immunotherapy Combined With Antimycotic Drug TMP- SMX to Treat Infection With Paracoccidioides brasiliensis. Front Immunol 2021;12:725882. [PMID: 34737741 DOI: 10.3389/fimmu.2021.725882] [Reference Citation Analysis]
40 Saleh D, Wang G, Mueller B, Rischawy F, Kluters S, Studts J, Hubbuch J. Cross-scale quality assessment of a mechanistic cation exchange chromatography model. Biotechnol Prog 2021;37:e3081. [PMID: 32926575 DOI: 10.1002/btpr.3081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Bogen JP, Grzeschik J, Jakobsen J, Bähre A, Hock B, Kolmar H. Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. Front Oncol 2021;11:672262. [PMID: 34123841 DOI: 10.3389/fonc.2021.672262] [Reference Citation Analysis]
42 Chang HP, Kim SJ, Shah DK. Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations. J Pharm Sci 2021;110:446-57. [PMID: 32502472 DOI: 10.1016/j.xphs.2020.05.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
43 Wang Q, Wang T, Zhang R, Yang S, McFarland KS, Chung CY, Jia H, Wang LX, Cipollo JF, Betenbaugh MJ. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions. Biotechnol Bioeng 2021. [PMID: 34647616 DOI: 10.1002/bit.27953] [Reference Citation Analysis]
44 Krawczyk K, Buchanan A, Marcatili P. Data mining patented antibody sequences. MAbs 2021;13:1892366. [PMID: 33722161 DOI: 10.1080/19420862.2021.1892366] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ita K. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. Arch Med Res 2021;52:15-24. [PMID: 32950264 DOI: 10.1016/j.arcmed.2020.09.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
46 Smith SN, Schubert R, Simic B, Brücher D, Schmid M, Kirk N, Freitag PC, Gradinaru V, Plückthun A. The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. Proc Natl Acad Sci U S A 2021;118:e2017925118. [PMID: 34001602 DOI: 10.1073/pnas.2017925118] [Reference Citation Analysis]
47 Lamendour L, Deluce-Kakwata-Nkor N, Mouline C, Gouilleux-Gruart V, Velge-Roussel F. Tethering Innate Surface Receptors on Dendritic Cells: A New Avenue for Immune Tolerance Induction? Int J Mol Sci 2020;21:E5259. [PMID: 32722168 DOI: 10.3390/ijms21155259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kreuzberger N, Hirsch C, Chai KL, Piechotta V, Valk SJ, Estcourt LJ, Salomon S, Tomlinson E, Monsef I, Wood EM, So-osman C, Roberts DJ, Mcquilten Z, Skoetz N; Cochrane Haematology Group. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013825] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Kiyoshi M, Tada M, Shibata H, Aoyama M, Ishii-Watabe A. Characterization of Aggregated Antibody-Silicone Oil Complexes: From Perspectives of Morphology, 3D Image, and Fcγ Receptor Activation. J Pharm Sci 2021;110:1189-96. [PMID: 33069712 DOI: 10.1016/j.xphs.2020.10.022] [Reference Citation Analysis]
50 Benedetti F, Stracke F, Stadlmayr G, Stadlbauer K, Rüker F, Wozniak-Knopp G. Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains. Biochem Biophys Rep 2021;26:100959. [PMID: 33718630 DOI: 10.1016/j.bbrep.2021.100959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kosuge H, Nagatoishi S, Kiyoshi M, Ishii-Watabe A, Tanaka T, Terao Y, Oe S, Ide T, Tsumoto K. Highly sensitive HPLC analysis and biophysical characterization of N-glycans of IgG-Fc domain in comparison between CHO and 293 cells using FcγRIIIa ligand. Biotechnol Prog 2020;36:e3016. [PMID: 32390308 DOI: 10.1002/btpr.3016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Choi JR, Kim MJ, Tae N, Wi TM, Kim SH, Lee ES, Kim DH. BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody. Viruses 2020;12:E684. [PMID: 32630442 DOI: 10.3390/v12060684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Brown TD, Habibi N, Wu D, Lahann J, Mitragotri S. Effect of Nanoparticle Composition, Size, Shape, and Stiffness on Penetration Across the Blood–Brain Barrier. ACS Biomater Sci Eng 2020;6:4916-28. [DOI: 10.1021/acsbiomaterials.0c00743] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
54 Verscheure L, Oosterlynck M, Cerdobbel A, Sandra P, Lynen F, Sandra K. Middle-up characterization of monoclonal antibodies by online reduction liquid chromatography-mass spectrometry. J Chromatogr A 2021;1637:461808. [PMID: 33385741 DOI: 10.1016/j.chroma.2020.461808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sun Y, Shi C, Zhang Q, Yao S, Slater NK, Lin D. Model-based process development and evaluation of twin-column continuous capture processes with Protein A affinity resin. Journal of Chromatography A 2020;1625:461300. [DOI: 10.1016/j.chroma.2020.461300] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
56 Cejkov M, Greer T, Johnson RO, Zheng X, Li N. Electron Transfer Dissociation Parameter Optimization Using Design of Experiments Increases Sequence Coverage of Monoclonal Antibodies. J Am Soc Mass Spectrom 2021;32:762-71. [PMID: 33596068 DOI: 10.1021/jasms.0c00458] [Reference Citation Analysis]
57 Nieraad H, de Bruin N, Arne O, Hofmann MCJ, Schmidt M, Saito T, Saido TC, Gurke R, Schmidt D, Till U, Parnham MJ, Geisslinger G. Impact of Hyperhomocysteinemia and Different Dietary Interventions on Cognitive Performance in a Knock-in Mouse Model for Alzheimer's Disease. Nutrients 2020;12:E3248. [PMID: 33114054 DOI: 10.3390/nu12113248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Lin DQ, Zhang QL, Yao SJ. Model-assisted approaches for continuous chromatography: Current situation and challenges. J Chromatogr A 2021;1637:461855. [PMID: 33445032 DOI: 10.1016/j.chroma.2020.461855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Hutchings CJ. Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. Antib Ther 2020;3:257-64. [PMID: 33912796 DOI: 10.1093/abt/tbaa023] [Reference Citation Analysis]
60 Menéndez-Arias L, Martín-Alonso S, Frutos-Beltrán E. An Update on Antiretroviral Therapy. Adv Exp Med Biol 2021;1322:31-61. [PMID: 34258736 DOI: 10.1007/978-981-16-0267-2_2] [Reference Citation Analysis]
61 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev 2021;9:CD013825. [PMID: 34473343 DOI: 10.1002/14651858.CD013825.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
62 Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, Kepp O. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology 2020;9:1796002. [PMID: 32934889 DOI: 10.1080/2162402X.2020.1796002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
63 Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, Wozniak-Knopp G, Rueker F, Leah R, McCafferty J. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs 2020;12:1829335. [PMID: 33103593 DOI: 10.1080/19420862.2020.1829335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
64 Zhou M, Yan Z, Li H, Liu X, Sun P. Application of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy in Predicting Protein Stability, Especially for Co-Formulated Antibodies. Pharm Res 2021;38:721-32. [PMID: 33754257 DOI: 10.1007/s11095-021-03026-8] [Reference Citation Analysis]
65 Cruzado-Park ID. Optimization of an IgG1 CIEF separation by using narrow-range ampholytes and DMSO as protein solubilizer. Electrophoresis 2020;41:1308-15. [PMID: 32375204 DOI: 10.1002/elps.201900449] [Reference Citation Analysis]
66 Soeda K, Fukuda M, Takahashi M, Imai H, Arai K, Saitoh S, Kishore RS, Oltra NS, Duboeuf J, Hashimoto D, Yamanaka Y. Impact of Poloxamer 188 Material Attributes on Proteinaceous Visible Particle Formation in Liquid Monoclonal Antibody Formulations. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.04.012] [Reference Citation Analysis]
67 Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, Mutair AA, Alhumaid S, Al-Omari A, Dhawan M, Tiwari R, Sharun K, Mohapatra RK, Mitra S, Bilal M, Alyami SA, Emran TB, Moni MA, Dhama K. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines (Basel) 2021;9:436. [PMID: 33946736 DOI: 10.3390/vaccines9050436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
68 Chen D, Zhao Y, Li M, Shang H, Li N, Li F, Wang W, Wang Y, Jin R, Liu S, Li X, Gao S, Tian Y, Li R, Li H, Zhang Y, Du M, Cao Y, Zhang Y, Li X, Huang Y, Hu LA, Li F, Zhang H. A general Fc engineering platform for the next generation of antibody therapeutics. Theranostics 2021;11:1901-17. [PMID: 33408788 DOI: 10.7150/thno.51299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
69 Kingsbury JS, Lantz MM, Saini A, Wang MZ, Gokarn YR. Characterization of Opalescence in low Volume Monoclonal Antibody Solutions Enabled by Microscale Nephelometry. J Pharm Sci 2021;110:3176-82. [PMID: 34004217 DOI: 10.1016/j.xphs.2021.05.005] [Reference Citation Analysis]
70 Bondarenko P, Nichols AC, Xiao G, Shi RL, Chan PK, Dillon TM, Garces F, Semin DJ, Ricci MS. Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes. MAbs 2021;13:1887629. [PMID: 33615991 DOI: 10.1080/19420862.2021.1887629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Fernández-Quintero ML, Georges G, Varga JM, Liedl KR. Ensembles in solution as a new paradigm for antibody structure prediction and design. MAbs 2021;13:1923122. [PMID: 34030577 DOI: 10.1080/19420862.2021.1923122] [Reference Citation Analysis]
72 Mravec B, Horvathova L, Hunakova L. Neurobiology of Cancer: the Role of β-Adrenergic Receptor Signaling in Various Tumor Environments. Int J Mol Sci 2020;21:E7958. [PMID: 33114769 DOI: 10.3390/ijms21217958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
73 Kini RM. Toxinology provides multidirectional and multidimensional opportunities: A personal perspective. Toxicon X 2020;6:100039. [PMID: 32550594 DOI: 10.1016/j.toxcx.2020.100039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Pedreño-Lopez N, Ricciardi MJ, Rosen BC, Song G, Andrabi R, Burton DR, Rakasz EG, Watkins DI. An Automated Fluorescence-Based Method to Isolate Bone Marrow-Derived Plasma Cells from Rhesus Macaques Using SIVmac239 SOSIP.664. Mol Ther Methods Clin Dev 2020;18:781-90. [PMID: 32953929 DOI: 10.1016/j.omtm.2020.08.004] [Reference Citation Analysis]
75 Yagi H, Yanaka S, Yogo R, Ikeda A, Onitsuka M, Yamazaki T, Kato T, Park EY, Yokoyama J, Kato K. Silkworm Pupae Function as Efficient Producers of Recombinant Glycoproteins with Stable-Isotope Labeling. Biomolecules 2020;10:E1482. [PMID: 33114581 DOI: 10.3390/biom10111482] [Reference Citation Analysis]
76 Nash A, Aghlara-Fotovat S, Hernandez A, Scull C, Veiseh O. Clinical translation of immunomodulatory therapeutics. Adv Drug Deliv Rev 2021;176:113896. [PMID: 34324885 DOI: 10.1016/j.addr.2021.113896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Simons JF, Lim YW, Carter KP, Wagner EK, Wayham N, Adler AS, Johnson DS. Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR. MAbs 2020;12:1803646. [PMID: 32744131 DOI: 10.1080/19420862.2020.1803646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Hutchings CJ. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update. Expert Opin Biol Ther 2020;20:925-35. [PMID: 32264722 DOI: 10.1080/14712598.2020.1745770] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
79 Deszyński P, Młokosiewicz J, Volanakis A, Jaszczyszyn I, Castellana N, Bonissone S, Ganesan R, Krawczyk K. INDI-integrated nanobody database for immunoinformatics. Nucleic Acids Res 2021:gkab1021. [PMID: 34747487 DOI: 10.1093/nar/gkab1021] [Reference Citation Analysis]
80 Gieselmann L, Kreer C, Ercanoglu MS, Lehnen N, Zehner M, Schommers P, Potthoff J, Gruell H, Klein F. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nat Protoc 2021;16:3639-71. [PMID: 34035500 DOI: 10.1038/s41596-021-00554-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Lin J, Lee SL, Russell AM, Huang RF, Batt MA, Chang SS, Ferrante A, Verdino P. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLoS One 2021;16:e0254944. [PMID: 34297759 DOI: 10.1371/journal.pone.0254944] [Reference Citation Analysis]
82 Maré A, D'Haese PC, Verhulst A. The Role of Sclerostin in Bone and Ectopic Calcification. Int J Mol Sci 2020;21:E3199. [PMID: 32366042 DOI: 10.3390/ijms21093199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
83 Dash R, Singh SK, Chirmule N, Rathore AS. Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review. AAPS J 2021;24:15. [PMID: 34931298 DOI: 10.1208/s12248-021-00671-0] [Reference Citation Analysis]
84 Stahel PF, Barnum SR. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option. Front Immunol 2020;11:1661. [PMID: 32733489 DOI: 10.3389/fimmu.2020.01661] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
85 Datta-Mannan A, Estwick S, Zhou C, Choi H, Douglass NE, Witcher DR, Lu J, Beidler C, Millican R. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. MAbs 2020;12:1770028. [PMID: 32486889 DOI: 10.1080/19420862.2020.1770028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 Hotinger JA, May AE. Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria. Antibodies (Basel) 2020;9:E35. [PMID: 32726928 DOI: 10.3390/antib9030035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Antibodies (Basel) 2020;9:E64. [PMID: 33212886 DOI: 10.3390/antib9040064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
88 Zheng F, Hou P, Corpstein CD, Xing L, Li T. Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Model Development. Pharm Res 2021;38:607-24. [PMID: 33811278 DOI: 10.1007/s11095-021-03032-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Akkın S, Varan G, Bilensoy E. A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers. Molecules 2021;26:3382. [PMID: 34205019 DOI: 10.3390/molecules26113382] [Reference Citation Analysis]
90 Jackobek R, Herrick-Wagman S, Zhu L, Francis C, Solbrand A, Eriksson C, Berg M, Go D, D'Antona AM. Automated pH and conductivity conditioning using feedback control to support a two-step continuous purification process. J Chromatogr A 2020;1630:461537. [PMID: 32961387 DOI: 10.1016/j.chroma.2020.461537] [Reference Citation Analysis]
91 Brierley GV, Webber H, Rasijeff E, Grocott S, Siddle K, Semple RK. Anti-Insulin Receptor Antibodies Improve Hyperglycemia in a Mouse Model of Human Insulin Receptoropathy. Diabetes 2020;69:2481-9. [PMID: 32816962 DOI: 10.2337/db20-0345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Klasen B, Moon ES, Rösch F. AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions. Nucl Med Biol 2021;96-97:80-93. [PMID: 33839678 DOI: 10.1016/j.nucmedbio.2021.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Waibl F, Fernández-Quintero ML, Kamenik AS, Kraml J, Hofer F, Kettenberger H, Georges G, Liedl KR. Conformational Ensembles of Antibodies Determine Their Hydrophobicity. Biophys J 2021;120:143-57. [PMID: 33220303 DOI: 10.1016/j.bpj.2020.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Charoenpattarapreeda J, Walsh SJ, Carroll JS, Spring DR. Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. Angew Chem Int Ed Engl 2020;59:23045-50. [PMID: 32894646 DOI: 10.1002/anie.202010090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
95 Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V, Stanke-Labesque F, Gautier-Veyret E. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem 2021;87:60-6. [PMID: 33096054 DOI: 10.1016/j.clinbiochem.2020.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
96 He K, Zeng S, Qian L. Recent progress in the molecular imaging of therapeutic monoclonal antibodies. J Pharm Anal 2020;10:397-413. [PMID: 33133724 DOI: 10.1016/j.jpha.2020.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Kinumi T, Saikusa K, Kato M, Kojima R, Igarashi C, Noda N, Honda S. Characterization and Value Assignment of a Monoclonal Antibody Reference Material, NMIJ RM 6208a, AIST-MAB. Front Mol Biosci 2022;9:842041. [DOI: 10.3389/fmolb.2022.842041] [Reference Citation Analysis]
98 El Abd Y, Tabll A, Smolic R, Smolic M. Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies - SARS CoV-2 as an example. Hum Antibodies 2022;30:15-24. [PMID: 34958012 DOI: 10.3233/HAB-211513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
99 Kuwahara A, Nagai K, Nakanishi T, Kumagai I, Asano R. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation. Int J Mol Sci 2020;21:E8914. [PMID: 33255436 DOI: 10.3390/ijms21238914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, Warwicker J, Martin ACR. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs 2022;14:2020082. [PMID: 35104168 DOI: 10.1080/19420862.2021.2020082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
101 Lodge JM, Schauer KL, Brademan DR, Riley NM, Shishkova E, Westphall MS, Coon JJ. Top-Down Characterization of an Intact Monoclonal Antibody Using Activated Ion Electron Transfer Dissociation. Anal Chem 2020;92:10246-51. [PMID: 32608969 DOI: 10.1021/acs.analchem.0c00705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
102 Lefebvre G, Maze A, Alvarez-Palencia Jimenez R, Bruckert F, Filipe V, Huille S, Weidenhaupt M. Surfactant Protection Efficacy at Surfaces Varies with the Nature of Hydrophobic Materials. Pharm Res 2021. [PMID: 34904200 DOI: 10.1007/s11095-021-03133-6] [Reference Citation Analysis]
103 Michigami M, Ramanayake Mudiyanselage TMR, Suzuki M, Ishizako H, Notsu K, Sugiura K, Fujii I. New Class of Drug Modalities: Directed Evolution of a De Novo Designed Helix-Loop-Helix Peptide to Bind VEGF for Tumor Growth Inhibition. ACS Chem Biol 2022;17:647-53. [PMID: 35176860 DOI: 10.1021/acschembio.1c00940] [Reference Citation Analysis]
104 Deal CE, Carfi A, Plante OJ. Advancements in mRNA Encoded Antibodies for Passive Immunotherapy. Vaccines (Basel) 2021;9:108. [PMID: 33572679 DOI: 10.3390/vaccines9020108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
105 Huang L, Zhou Y, Sun Q, Cao L, Zhang X. Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma. Cancer Biomark 2021. [PMID: 34459388 DOI: 10.3233/CBM-210178] [Reference Citation Analysis]
106 Germovsek E, Cheng M, Giragossian C. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. MAbs 2021;13:1964935. [PMID: 34530672 DOI: 10.1080/19420862.2021.1964935] [Reference Citation Analysis]
107 Saleh D, Hess R, Ahlers-Hesse M, Beckert N, Schönberger M, Rischawy F, Wang G, Bauer J, Blech M, Kluters S, Studts J, Hubbuch J. Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography. Biotechnol Bioeng 2021;118:2923-33. [PMID: 33871060 DOI: 10.1002/bit.27798] [Reference Citation Analysis]
108 Pretto F, Fitzgerald RE. In vivo safety testing of Antibody Drug Conjugates. Regulatory Toxicology and Pharmacology 2021;122:104890. [DOI: 10.1016/j.yrtph.2021.104890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Santos-Neto JF, Oliveira FO, Hodel KVS, Fonseca LMS, Badaró R, Machado BAS. Technological Advancements in Monoclonal Antibodies. ScientificWorldJournal 2021;2021:6663708. [PMID: 33628140 DOI: 10.1155/2021/6663708] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Dunlap T, Cao Y. Physiological Considerations for Modeling in vivo Antibody-Target Interactions. Front Pharmacol 2022;13:856961. [PMID: 35281913 DOI: 10.3389/fphar.2022.856961] [Reference Citation Analysis]
111 Apgar JR, Tam ASP, Sorm R, Moesta S, King AC, Yang H, Kelleher K, Murphy D, D'Antona AM, Yan G, Zhong X, Rodriguez L, Ma W, Ferguson DE, Carven GJ, Bennett EM, Lin L. Modeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design. PLoS One 2020;15:e0232713. [PMID: 32379792 DOI: 10.1371/journal.pone.0232713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
112 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
113 Lee BI, Park SJ, Park Y, Shin SH, Choi JM, Park MJ, Lim JH, Kim SY, Lee H, Shin YG. Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay. Pharmaceutics 2021;13:125. [PMID: 33478046 DOI: 10.3390/pharmaceutics13010125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zhu L, Liu J, Zhou G, Liu TM, Dai Y, Nie G, Zhao Q. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy. Small 2021;:e2102624. [PMID: 34378338 DOI: 10.1002/smll.202102624] [Reference Citation Analysis]
115 Brown DG, Wobst HJ. A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. J Med Chem 2021;64:2312-38. [PMID: 33617254 DOI: 10.1021/acs.jmedchem.0c01516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
116 Yu CW, Yau M, Mezey N, Joarder I, Micieli JA. Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review. Eye Brain 2020;12:139-67. [PMID: 33173368 DOI: 10.2147/EB.S277760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Wolf Pérez AM, Lorenzen N, Vendruscolo M, Sormanni P. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods. Methods Mol Biol 2022;2313:57-113. [PMID: 34478132 DOI: 10.1007/978-1-0716-1450-1_4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
118 Mason C, Gimblet GR, Lapi SE, Lewis JS. Novel Tracers and Radionuclides in PET Imaging. Radiol Clin North Am 2021;59:887-918. [PMID: 34392925 DOI: 10.1016/j.rcl.2021.05.012] [Reference Citation Analysis]
119 Deuschle FC, Ilyukhina E, Skerra A. Anticalin® proteins: from bench to bedside. Expert Opin Biol Ther 2021;21:509-18. [PMID: 33074019 DOI: 10.1080/14712598.2021.1839046] [Reference Citation Analysis]
120 Tajiri-Tsukada M, Hashii N, Ishii-Watabe A. Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies. Bioengineered 2020;11:984-1000. [PMID: 32942957 DOI: 10.1080/21655979.2020.1814683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
121 Das R, Langou S, Le TT, Prasad P, Lin F, Nguyen TD. Electrical Stimulation for Immune Modulation in Cancer Treatments. Front Bioeng Biotechnol 2021;9:795300. [PMID: 35087799 DOI: 10.3389/fbioe.2021.795300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs. Immunol Cell Biol 2020;98:287-304. [PMID: 32157732 DOI: 10.1111/imcb.12326] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
123 Demaria O, Gauthier L, Debroas G, Vivier E. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments. Eur J Immunol 2021;51:1934-42. [PMID: 34145579 DOI: 10.1002/eji.202048953] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
124 Lou W, Stimple SD, Desai AA, Makowski EK, Kalyoncu S, Mogensen JE, Spang LT, Asgreen DJ, Staby A, Duus K, Amstrup J, Zhang Y, Tessier PM. Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations. Biotechnol Bioeng 2021;118:797-808. [PMID: 33095442 DOI: 10.1002/bit.27610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Zhou Y, Xie S, Yang Y, Jiang L, Liu S, Li W, Abagna HB, Ning L, Huang J. SSH2.0: A Better Tool for Predicting the Hydrophobic Interaction Risk of Monoclonal Antibody. Front Genet 2022;13:842127. [PMID: 35368659 DOI: 10.3389/fgene.2022.842127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Sinharoy P, McFarland KS, Majewska NI, Betenbaugh MJ, Handlogten MW. Redox as a bioprocess parameter: analytical redox quantification in biological therapeutic production. Curr Opin Biotechnol 2021;71:49-54. [PMID: 34243034 DOI: 10.1016/j.copbio.2021.06.017] [Reference Citation Analysis]
127 Palte RL, Juan V, Gomez-Llorente Y, Bailly MA, Chakravarthy K, Chen X, Cipriano D, Fayadat-Dilman L, Gathiaka S, Greb H, Hall B, Handa M, Hsieh M, Kofman E, Lin H, Miller JR, Nguyen N, O'Neil J, Shaheen H, Sterner E, Strickland C, Sun A, Taremi S, Scapin G. Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action. Commun Biol 2021;4:927. [PMID: 34326456 DOI: 10.1038/s42003-021-02444-z] [Reference Citation Analysis]
128 Serna N, Pallarès V, Unzueta U, Garcia-Leon A, Voltà-Durán E, Sánchez-Chardi A, Parladé E, Rueda A, Casanova I, Falgàs A, Alba-Castellón L, Sierra J, Villaverde A, Vázquez E, Mangues R. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. J Control Release 2022;343:277-87. [PMID: 35051493 DOI: 10.1016/j.jconrel.2022.01.017] [Reference Citation Analysis]
129 Heinhuis KM, Barkman HJ, Beijnen JH, Hendrikx JJMA. A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute. Int J Clin Pharm 2021;43:181-90. [PMID: 32909221 DOI: 10.1007/s11096-020-01131-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Zhou Q, Jaworski J, Zhou Y, Valente D, Cotton J, Honey D, Boudanova E, Beninga J, Rao E, Wei R, Mauriac C, Pan C, Park A, Qiu H. Engineered Fc-glycosylation switch to eliminate antibody effector function. MAbs 2020;12:1814583. [PMID: 32892677 DOI: 10.1080/19420862.2020.1814583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
131 Ke Q, Kroger CJ, Clark M, Tisch RM. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. Front Immunol 2020;11:624568. [PMID: 33679717 DOI: 10.3389/fimmu.2020.624568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
132 Lin M, Paolillo V, Le DB, Macapinlac H, Ravizzini GC. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer 2021;45:100796. [PMID: 34657748 DOI: 10.1016/j.currproblcancer.2021.100796] [Reference Citation Analysis]
133 Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem 2021;32:1315-30. [PMID: 33974403 DOI: 10.1021/acs.bioconjchem.1c00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Kobayashi K, Tahara H, Kagawa Y. A method combining blue native polyacrylamide gel electrophoresis with liquid chromatography tandem-mass spectrometry to detect circulating immune complexes between therapeutic monoclonal antibodies and anti-drug antibodies in animals. J Pharm Biomed Anal 2020;186:113329. [PMID: 32371323 DOI: 10.1016/j.jpba.2020.113329] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Saad MH, El-Fakharany EM, Salem MS, Sidkey NM. The use of cyanobacterial metabolites as natural medical and biotechnological tools: review article. J Biomol Struct Dyn 2020;:1-23. [PMID: 33164673 DOI: 10.1080/07391102.2020.1838948] [Reference Citation Analysis]
136 Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol 2021;18:805-28. [PMID: 32879472 DOI: 10.1038/s41423-020-00530-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
137 Dodd R, Schofield DJ, Wilkinson T, Britton ZT. Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: Overcoming the antigen challenge and enabling discovery strategies. Methods 2020;180:111-26. [PMID: 32422249 DOI: 10.1016/j.ymeth.2020.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
138 Li M, Lin D, Yao S, Zhang Q. Study on antibody adsorption and elution performance of carboxyl and hydrophobic groups on mixed-mode ligands. J Sep Sci 2022. [PMID: 35716379 DOI: 10.1002/jssc.202200342] [Reference Citation Analysis]
139 Bogen JP, Storka J, Yanakieva D, Fiebig D, Grzeschik J, Hock B, Kolmar H. Isolation of Common Light Chain Antibodies from Immunized Chickens Using Yeast Biopanning and Fluorescence-Activated Cell Sorting. Biotechnol J 2021;16:e2000240. [PMID: 32914549 DOI: 10.1002/biot.202000240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
140 Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today 2021;26:951-67. [PMID: 33450394 DOI: 10.1016/j.drudis.2021.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
141 Ghosh K, Ghosh K. Monoclonal antibodies used for the management of haematological disorders. Expert Rev Hematol 2022. [PMID: 35504000 DOI: 10.1080/17474086.2022.2073213] [Reference Citation Analysis]
142 Zhao P, Gunawardena HP, Zhong X, Zare RN, Chen H. Microdroplet Ultrafast Reactions Speed Antibody Characterization. Anal Chem 2021;93:3997-4005. [PMID: 33590747 DOI: 10.1021/acs.analchem.0c04974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
143 Sevy AM, Chen M, Castor M, Sylvia T, Krishnamurthy H, Ishchenko A, Hsieh C. Structure- and sequence-based design of synthetic single-domain antibody libraries. Protein Engineering, Design and Selection 2020;33:gzaa028. [DOI: 10.1093/protein/gzaa028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
144 Fernández-Quintero ML, Kroell KB, Hofer F, Riccabona JR, Liedl KR. Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution. Front Immunol 2021;12:630034. [PMID: 33737932 DOI: 10.3389/fimmu.2021.630034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
145 Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y, Kuga H. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica 2020;50:1242-50. [PMID: 32306807 DOI: 10.1080/00498254.2020.1755909] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
146 Qing R, Hao S, Smorodina E, Jin D, Zalevsky A, Zhang S. Protein Design: From the Aspect of Water Solubility and Stability. Chem Rev 2022. [PMID: 35921495 DOI: 10.1021/acs.chemrev.1c00757] [Reference Citation Analysis]
147 Klaus T, Deshmukh S. pH-responsive antibodies for therapeutic applications. J Biomed Sci 2021;28:11. [PMID: 33482842 DOI: 10.1186/s12929-021-00709-7] [Reference Citation Analysis]
148 Sawant MS, Streu CN, Wu L, Tessier PM. Toward Drug-Like Multispecific Antibodies by Design. Int J Mol Sci 2020;21:E7496. [PMID: 33053650 DOI: 10.3390/ijms21207496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
149 Atsumi Y, Sakurai N, Nishimura K, Yamazaki K, Wakamatsu K. Identification and Characterization of a Monoclonal Antibody Variant Species with a Clipping in the Complementarity Determining Region Isolated by Size Exclusion Chromatography Under Native Conditions. J Pharm Sci 2021:S0022-3549(21)00288-4. [PMID: 34089708 DOI: 10.1016/j.xphs.2021.05.023] [Reference Citation Analysis]
150 Fatima SW, Khare SK. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J Control Release 2021;341:555-65. [PMID: 34906604 DOI: 10.1016/j.jconrel.2021.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
151 Depetris RS, Lu D, Polonskaya Z, Zhang Z, Luna X, Tankard A, Kolahi P, Drummond M, Williams C, Ebert MCCJC, Patel JP, Poyurovsky MV. Functional antibody characterization via direct structural analysis and information-driven protein-protein docking. Proteins 2021. [PMID: 34773424 DOI: 10.1002/prot.26280] [Reference Citation Analysis]
152 Miyafusa T, Watanabe H, Honda S. Local disorder of the C-terminal segment of the heavy chain as a common sign of stressed antibodies evidenced with a peptide affinity probe specific to non-native IgG. Int J Biol Macromol 2021;182:1697-703. [PMID: 34048835 DOI: 10.1016/j.ijbiomac.2021.05.137] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Kallolimath S, Hackl T, Gahn R, Grünwald-Gruber C, Zich W, Kogelmann B, Lux A, Nimmerjahn F, Steinkellner H. Expression Profiling and Glycan Engineering of IgG Subclass 1-4 in Nicotiana benthamiana. Front Bioeng Biotechnol 2020;8:825. [PMID: 32793574 DOI: 10.3389/fbioe.2020.00825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
154 James BH, Papakyriacou P, Gardener MJ, Gliddon L, Weston CJ, Lalor PF. The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody. Front Physiol 2022;12:753833. [DOI: 10.3389/fphys.2021.753833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
155 Haberger M, Heidenreich AK, Hook M, Fichtl J, Lang R, Cymer F, Adibzadeh M, Kuhne F, Wegele H, Reusch D, Bonnington L, Bulau P. Multiattribute Monitoring of Antibody Charge Variants by Cation-Exchange Chromatography Coupled to Native Mass Spectrometry. J Am Soc Mass Spectrom 2021;32:2062-71. [PMID: 33687195 DOI: 10.1021/jasms.0c00446] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
156 Dixon KJ, Wu J, Walcheck B. Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells. Cancers (Basel) 2021;13:312. [PMID: 33467027 DOI: 10.3390/cancers13020312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
157 Shivva V, Boswell CA, Rafidi H, Kelley RF, Kamath AV, Crowell SR. Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics. Front Pharmacol 2021;12:601569. [PMID: 34025395 DOI: 10.3389/fphar.2021.601569] [Reference Citation Analysis]
158 Fernández-Quintero ML, Kroell KB, Grunewald LJ, Fischer AM, Riccabona JR, Liedl KR. CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies. MAbs 2022;14:2024118. [PMID: 35090383 DOI: 10.1080/19420862.2021.2024118] [Reference Citation Analysis]
159 Ahangarzadeh S, Payandeh Z, Arezumand R, Shahzamani K, Yarian F, Alibakhshi A. An update on antiviral antibody-based biopharmaceuticals. Int Immunopharmacol 2020;86:106760. [PMID: 32645633 DOI: 10.1016/j.intimp.2020.106760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
160 Wahane A, Waghmode A, Kapphahn A, Dhuri K, Gupta A, Bahal R. Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy. Molecules 2020;25:E2866. [PMID: 32580326 DOI: 10.3390/molecules25122866] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
161 Furtmann N, Schneider M, Spindler N, Steinmann B, Li Z, Focken I, Meyer J, Dimova D, Kroll K, Leuschner WD, Debeaumont A, Mathieu M, Lange C, Dittrich W, Kruip J, Schmidt T, Birkenfeld J. An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics. MAbs 2021;13:1955433. [PMID: 34382900 DOI: 10.1080/19420862.2021.1955433] [Reference Citation Analysis]
162 Lecerf M, Kanyavuz A, Rossini S, Dimitrov JD. Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities. Commun Biol 2021;4:391. [PMID: 33758329 DOI: 10.1038/s42003-021-01931-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Heo K, Lee S. TSPAN8 as a Novel Emerging Therapeutic Target in Cancer for Monoclonal Antibody Therapy. Biomolecules 2020;10:E388. [PMID: 32138170 DOI: 10.3390/biom10030388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
164 Nguyen TT, Ho AS, Nguyen TK, Nguyen TN, Bui VC, Nguyen TB, Dang HH, Nguyen DK, Nguyen TN, Nguyen LT. Efficacy of nimotuzumab (hR3) conjugated with 131I or 90Y in laryngeal carcinoma xenograft mouse model. Int J Radiat Biol 2021;97:704-13. [PMID: 33617414 DOI: 10.1080/09553002.2021.1889703] [Reference Citation Analysis]
165 Michigami M, Takahashi K, Yamashita H, Ye Z, Nakase I, Fujii I. A "ligand-targeting" peptide-drug conjugate: Targeted intracellular drug delivery by VEGF-binding helix-loop-helix peptides via receptor-mediated endocytosis. PLoS One 2021;16:e0247045. [PMID: 33630870 DOI: 10.1371/journal.pone.0247045] [Reference Citation Analysis]
166 Lefebvre G, Bruckert F, Filipe V, Huille S, Weidenhaupt M. Adsorption rate constants of therapeutic proteins and surfactants for material surfaces. Colloids Surf B Biointerfaces 2021;203:111722. [PMID: 33839475 DOI: 10.1016/j.colsurfb.2021.111722] [Reference Citation Analysis]
167 Onogi S, Lee SH, Fruehauf KR, Shea KJ. Abiotic Stimuli-Responsive Protein Affinity Reagent for IgG. Biomacromolecules 2021;22:2641-8. [PMID: 34009976 DOI: 10.1021/acs.biomac.1c00335] [Reference Citation Analysis]
168 Yamano-Adachi N, Arishima R, Puriwat S, Omasa T. Establishment of fast-growing serum-free immortalised cells from Chinese hamster lung tissues for biopharmaceutical production. Sci Rep 2020;10:17612. [PMID: 33077772 DOI: 10.1038/s41598-020-74735-0] [Reference Citation Analysis]
169 Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
170 Hanna KS, Larson S, Nguyen J, Boudreau J, Bulin J, Rolf M. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. Am J Health Syst Pharm 2021:zxab464. [PMID: 34864835 DOI: 10.1093/ajhp/zxab464] [Reference Citation Analysis]
171 Radosa JC, Stotz L, Müller C, Kaya AC, Solomayer EF, Radosa MP. Clinical Data on Immunotherapy in Breast Cancer. Breast Care (Basel) 2020;15:450-69. [PMID: 33223989 DOI: 10.1159/000511788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
172 Pythoud N, Bons J, Mijola G, Beck A, Cianférani S, Carapito C. Optimized Sample Preparation and Data Processing of Data-Independent Acquisition Methods for the Robust Quantification of Trace-Level Host Cell Protein Impurities in Antibody Drug Products. J Proteome Res 2021;20:923-31. [PMID: 33016074 DOI: 10.1021/acs.jproteome.0c00664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
173 Lu J, Ding J, Liu Z, Chen T. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). Int J Oncol 2022;60:12. [PMID: 34981814 DOI: 10.3892/ijo.2022.5302] [Reference Citation Analysis]
174 Shibata H, Terabe M, Shibano Y, Saitoh S, Takasugi T, Hayashi Y, Okabe S, Yamaguchi Y, Yasukawa H, Suetomo H, Miyanabe K, Ohbayashi N, Akimaru M, Saito S, Ito D, Nakano A, Kojima S, Miyahara Y, Sasaki K, Maruno T, Noda M, Kiyoshi M, Harazono A, Torisu T, Uchiyama S, Ishii-Watabe A. A Collaborative Study on the Classification of Silicone Oil Droplets and Protein Particles Using Flow Imaging Method. J Pharm Sci 2022:S0022-3549(22)00298-2. [PMID: 35839866 DOI: 10.1016/j.xphs.2022.07.006] [Reference Citation Analysis]
175 Motley MP, Diago-Navarro E, Banerjee K, Inzerillo S, Fries BC. The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant Klebsiella pneumoniae. mBio 2020;11:e02059-20. [PMID: 32900809 DOI: 10.1128/mBio.02059-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Beattie JW, Rowland-Jones RC, Farys M, Tran R, Kazarian SG, Byrne B. Insight into purification of monoclonal antibodies in industrial columns via studies of Protein A binding capacity by in situ ATR-FTIR spectroscopy. Analyst 2021;146:5177-85. [PMID: 34296229 DOI: 10.1039/d1an00985k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 van der Horst HJ, Nijhof IS, Mutis T, Chamuleau MED. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies. Cancers (Basel) 2020;12:E3041. [PMID: 33086644 DOI: 10.3390/cancers12103041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
178 Li G, Suzuki H, Asano T, Tanaka T, Suzuki H, Kaneko MK, Kato Y. Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications. Antibodies (Basel) 2022;11:41. [PMID: 35735360 DOI: 10.3390/antib11020041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Lin CW, Zheng T, Grande G, Nanna AR, Rader C, Lerner RA. A new immunochemical strategy for triple-negative breast cancer therapy. Sci Rep 2021;11:14875. [PMID: 34290315 DOI: 10.1038/s41598-021-94230-4] [Reference Citation Analysis]
180 Lin CW, Lerner RA. Antibody Libraries as Tools to Discover Functional Antibodies and Receptor Pleiotropism. Int J Mol Sci 2021;22:4123. [PMID: 33923551 DOI: 10.3390/ijms22084123] [Reference Citation Analysis]
181 Sulea T. Humanization of Camelid Single-Domain Antibodies. Methods Mol Biol 2022;2446:299-312. [PMID: 35157279 DOI: 10.1007/978-1-0716-2075-5_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Valtonen S, Vuorinen E, Eskonen V, Malakoutikhah M, Kopra K, Härmä H. Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies. MAbs 2021;13:1955810. [PMID: 34455913 DOI: 10.1080/19420862.2021.1955810] [Reference Citation Analysis]
183 Fasano M, Perri F, Della Corte CM, Di Liello R, Della Vittoria Scarpati G, Cascella M, Ottaiano A, Ciardiello F, Solla R. Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. Biomedicines 2021;9:1045. [PMID: 34440249 DOI: 10.3390/biomedicines9081045] [Reference Citation Analysis]
184 Gu Y, Xu H, Tang D. Mechanisms of Primary Membranous Nephropathy. Biomolecules 2021;11:513. [PMID: 33808418 DOI: 10.3390/biom11040513] [Reference Citation Analysis]
185 Joshi S, Joshi M, Degani MS. Tackling SARS-CoV-2: proposed targets and repurposed drugs. Future Med Chem 2020;12:1579-601. [PMID: 32564623 DOI: 10.4155/fmc-2020-0147] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
186 Lieu R, Antonysamy S, Druzina Z, Ho C, Kang NR, Pustilnik A, Wang J, Atwell S. Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. PLoS One 2020;15:e0232311. [PMID: 32915778 DOI: 10.1371/journal.pone.0232311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
187 Groen SS, Sinkeviciute D, Bay-Jensen AC, Thudium CS, Karsdal MA, Thomsen SF, Schett G, Nielsen SH. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev 2021;20:102760. [PMID: 33485992 DOI: 10.1016/j.autrev.2021.102760] [Reference Citation Analysis]
188 Nilvebrant J, Ereño-Orbea J, Gorelik M, Julian MC, Tessier PM, Julien JP, Sidhu SS. Systematic Engineering of Optimized Autonomous Heavy-Chain Variable Domains. J Mol Biol 2021;433:167241. [PMID: 34508727 DOI: 10.1016/j.jmb.2021.167241] [Reference Citation Analysis]
189 Narayanan H, Sponchioni M, Morbidelli M. Integration and digitalization in the manufacturing of therapeutic proteins. Chemical Engineering Science 2022;248:117159. [DOI: 10.1016/j.ces.2021.117159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
190 Afzal MA, Bhojane PP, Rathore AS. A simple, rapid, and robust "on-the-go" identity testing of biotherapeutics using FTIR spectroscopy. Electrophoresis 2021;42:1655-64. [PMID: 34021613 DOI: 10.1002/elps.202100045] [Reference Citation Analysis]
191 Tan Z, Ehamparanathan V, Ren T, Tang P, Hoffman L, Kuang J, Liu P, Huang C, Du C, Tao L, Chemmalil L, Lewandowski A, Ghose S, Li ZJ, Liu S. On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies. MAbs 2020;12:1829333. [PMID: 33016217 DOI: 10.1080/19420862.2020.1829333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Wang C, Hong J, Yang Z, Zhou X, Yang Y, Kong Y, Chen B, Wu H, Qian B, Dimitrov DS, Zhou X, Wu Y, Ying T. Design of a Novel Fab‐Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods. [DOI: 10.1002/smtd.202100966] [Reference Citation Analysis]
193 Montella L, Altucci L, Sarno F, Buonerba C, De Simone S, Facchini BA, Franzese E, De Vita F, Tafuto S, Berretta M, Facchini G. Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. Cancers (Basel) 2021;13:2359. [PMID: 34068344 DOI: 10.3390/cancers13102359] [Reference Citation Analysis]
194 Ma K, Mi CL, Cao XX, Wang TY. Progress of cationic gene delivery reagents for non-viral vector. Appl Microbiol Biotechnol 2021;105:525-38. [PMID: 33394152 DOI: 10.1007/s00253-020-11028-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
195 Zetterberg H, Stomrud E. Alzheimer's disease in primary care: new tools for improved and simplified diagnostics. J Intern Med 2021;290:477-9. [PMID: 33547829 DOI: 10.1111/joim.13249] [Reference Citation Analysis]
196 Kang K, Kim K, Lee SR, Kim Y, Lee JE, Lee YS, Lim JH, Lim CS, Kim YJ, Baek SI, Song DH, Hong JT, Kim DY. Selection and Characterization of YKL-40-Targeting Monoclonal Antibodies from Human Synthetic Fab Phage Display Libraries. Int J Mol Sci 2020;21:E6354. [PMID: 32883029 DOI: 10.3390/ijms21176354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
197 Wang S, Liu AP, Li N. An 18O-Labeling Assisted LC-MS Method for Accurate Quantitation of Unprocessed C-Terminal Lysine in Therapeutic Monoclonal Antibodies. J Am Soc Mass Spectrom 2020;31:1587-92. [PMID: 32515589 DOI: 10.1021/jasms.0c00149] [Reference Citation Analysis]
198 Kasherman L, Ahrari S, Lheureux S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol 2021;17:877-92. [PMID: 33251877 DOI: 10.2217/fon-2020-0655] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
199 Zhang R, Prabakaran P, Yu X, Mackness BC, Boudanova E, Hopke J, Sancho J, Saleh J, Cho H, Zhang N, Simonds-Mannes H, Stimple SD, Hoffmann D, Park A, Chowdhury PS, Rao SP. A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies. MAbs 2021;13:1904546. [PMID: 33899674 DOI: 10.1080/19420862.2021.1904546] [Reference Citation Analysis]
200 Valldorf B, Hinz SC, Russo G, Pekar L, Mohr L, Klemm J, Doerner A, Krah S, Hust M, Zielonka S. Antibody display technologies: selecting the cream of the crop. Biol Chem 2021. [PMID: 33759431 DOI: 10.1515/hsz-2020-0377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Tsumura K, Hsu W, Mimura M, Horiuchi A, Shiraki K. Lowering the viscosity of a high-concentration antibody solution by protein-polyelectrolyte complex. J Biosci Bioeng 2021:S1389-1723(21)00243-7. [PMID: 34629298 DOI: 10.1016/j.jbiosc.2021.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Zhang J, Vernes JM, Wen X, Oh E, Scales SJ, Meng YG. Reproducible quantification of IgG uptake at endogenous and overexpressed FcRn levels at pH 7.4: Comparison of a wild type IgG and a stronger FcRn binding variant. J Immunol Methods 2020;480:112767. [PMID: 32119889 DOI: 10.1016/j.jim.2020.112767] [Reference Citation Analysis]
203 Saleh D, Wang G, Rischawy F, Kluters S, Studts J, Hubbuch J. In silico process characterization for biopharmaceutical development following the quality by design concept. Biotechnol Prog 2021;:e3196. [PMID: 34309240 DOI: 10.1002/btpr.3196] [Reference Citation Analysis]
204 Zhang Y, Wu BJ, Yu X, Luo P, Ye H, Yu Y, Han W, Li J. Development of an Antigen-Antibody Co-Display System for Detecting Interaction of G-Protein-Coupled Receptors and Single-Chain Variable Fragments. Int J Mol Sci 2021;22:4711. [PMID: 33946798 DOI: 10.3390/ijms22094711] [Reference Citation Analysis]
205 Sultan EY, Rizk DE, Kenawy HI, Hassan R. A small fragment of factor B as a potential inhibitor of complement alternative pathway activity. Immunobiology 2021;226:152106. [PMID: 34147816 DOI: 10.1016/j.imbio.2021.152106] [Reference Citation Analysis]
206 Camperi J, Goyon A, Guillarme D, Zhang K, Stella C. Multi-dimensional LC-MS: the next generation characterization of antibody-based therapeutics by unified online bottom-up, middle-up and intact approaches. Analyst 2021;146:747-69. [DOI: 10.1039/d0an01963a] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
207 Somiya M, Kuroda S. Virus-mimicking nanocarriers for the intracellular delivery of therapeutic biomolecules. Nanomedicine (Lond) 2020;15:1163-5. [PMID: 32292099 DOI: 10.2217/nnm-2020-0078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Skeene K, Khatri K, Soloviev Z, Lapthorn C. Current status and future prospects for ion-mobility mass spectrometry in the biopharmaceutical industry. Biochim Biophys Acta Proteins Proteom 2021;:140697. [PMID: 34246790 DOI: 10.1016/j.bbapap.2021.140697] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Esnault C, Leblond V, Martin C, Desgranges A, Baltus CB, Aubrey N, Lakhrif Z, Lajoie L, Lantier L, Clémenceau B, Sarma B, Schrama J, Houben R, Schrama D, Hesbacher S, Gouilleux-Gruart V, Feng Y, Dimitrov D, Guyétant S, Berthon P, Viaud-Massuard MC, Samimi M, Touzé A, Kervarrec T. Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol 2021. [PMID: 34582565 DOI: 10.1111/bjd.20770] [Reference Citation Analysis]
210 Wu HH, Garidel P, Michaela B. HP-β-CD for the formulation of IgG and Ig-based biotherapeutics. Int J Pharm 2021;601:120531. [PMID: 33775727 DOI: 10.1016/j.ijpharm.2021.120531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Slemmons KK, Mukherjee S, Meltzer P, Purcell JW, Helman LJ. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr Blood Cancer 2021;68:e28771. [PMID: 33063919 DOI: 10.1002/pbc.28771] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Chu X, Yang X, Shi Q, Dong X, Sun Y. Kinetic and molecular insight into immunoglobulin G binding to immobilized recombinant protein A of different orientations. Journal of Chromatography A 2022;1671:463040. [DOI: 10.1016/j.chroma.2022.463040] [Reference Citation Analysis]
213 Srzentić K, Fornelli L, Tsybin YO, Loo JA, Seckler H, Agar JN, Anderson LC, Bai DL, Beck A, Brodbelt JS, van der Burgt YEM, Chamot-Rooke J, Chatterjee S, Chen Y, Clarke DJ, Danis PO, Diedrich JK, D'Ippolito RA, Dupré M, Gasilova N, Ge Y, Goo YA, Goodlett DR, Greer S, Haselmann KF, He L, Hendrickson CL, Hinkle JD, Holt MV, Hughes S, Hunt DF, Kelleher NL, Kozhinov AN, Lin Z, Malosse C, Marshall AG, Menin L, Millikin RJ, Nagornov KO, Nicolardi S, Paša-Tolić L, Pengelley S, Quebbemann NR, Resemann A, Sandoval W, Sarin R, Schmitt ND, Shabanowitz J, Shaw JB, Shortreed MR, Smith LM, Sobott F, Suckau D, Toby T, Weisbrod CR, Wildburger NC, Yates JR 3rd, Yoon SH, Young NL, Zhou M. Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass Spectrometry. J Am Soc Mass Spectrom 2020;31:1783-802. [PMID: 32812765 DOI: 10.1021/jasms.0c00036] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
214 Fernández-Quintero ML, Kroell KB, Heiss MC, Loeffler JR, Quoika PK, Waibl F, Bujotzek A, Moessner E, Georges G, Liedl KR. Surprisingly Fast Interface and Elbow Angle Dynamics of Antigen-Binding Fragments. Front Mol Biosci 2020;7:609088. [PMID: 33330636 DOI: 10.3389/fmolb.2020.609088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
215 Antipova NV, Larionova TD, Siniavin AE, Nikiforova MA, Gushchin VA, Babichenko II, Volkov AV, Shakhparonov MI, Pavlyukov MS. Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2. Int J Mol Sci 2020;21:E9167. [PMID: 33271925 DOI: 10.3390/ijms21239167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
216 Pekar L, Busch M, Valldorf B, Hinz SC, Toleikis L, Krah S, Zielonka S. Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform. MAbs 2020;12:1812210. [PMID: 32887531 DOI: 10.1080/19420862.2020.1812210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
217 Dimitrov JD. Harnessing the Therapeutic Potential of 'Rogue' Antibodies. Trends Pharmacol Sci 2020;41:409-17. [PMID: 32334839 DOI: 10.1016/j.tips.2020.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
218 Alsuliman T, Alasadi L, Alkharat B, Srour M, Alrstom A. A review of potential treatments to date in COVID-19 patients according to the stage of the disease. Curr Res Transl Med 2020;68:93-104. [PMID: 32540367 DOI: 10.1016/j.retram.2020.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
219 Apostol I, Bondarenko PV, Ren D, Semin DJ, Wu CH, Zhang Z, Goudar CT. Enabling development, manufacturing, and regulatory approval of biotherapeutics through advances in mass spectrometry. Curr Opin Biotechnol 2021;71:206-15. [PMID: 34508981 DOI: 10.1016/j.copbio.2021.08.001] [Reference Citation Analysis]
220 Rodrigues D, Tanenbaum LM, Thirumangalathu R, Somani S, Zhang K, Kumar V, Amin K, Thakkar SV. Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development. J Pharm Sci 2021;110:1077-82. [PMID: 33340533 DOI: 10.1016/j.xphs.2020.12.016] [Reference Citation Analysis]
221 Mimura Y, Saldova R, Mimura-Kimura Y, Rudd PM, Jefferis R. Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation. Exp Suppl 2021;112:481-517. [PMID: 34687020 DOI: 10.1007/978-3-030-76912-3_15] [Reference Citation Analysis]
222 Gao Y, Chen Z, Yang C, Zhong D. Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum. J Pharm Anal 2021;11:472-9. [PMID: 34513123 DOI: 10.1016/j.jpha.2020.08.005] [Reference Citation Analysis]
223 Yang J, Song QY, Niu SX, Chen HJ, Petersen RB, Zhang Y, Huang K. Emerging roles of angiopoietin-like proteins in inflammation: Mechanisms and potential as pharmacological targets. J Cell Physiol 2021. [PMID: 34289108 DOI: 10.1002/jcp.30534] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Narayanan H, Dingfelder F, Butté A, Lorenzen N, Sokolov M, Arosio P. Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation. Trends in Pharmacological Sciences 2021;42:151-65. [DOI: 10.1016/j.tips.2020.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
225 Woodall DW, Dillon TM, Kalenian K, Padaki R, Kuhns S, Semin DJ, Bondarenko PV. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry. MAbs 2022;14:2004982. [PMID: 34978527 DOI: 10.1080/19420862.2021.2004982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Haraya K, Tachibana T. Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data. Clin Pharmacokinet 2021. [PMID: 33954956 DOI: 10.1007/s40262-021-01023-z] [Reference Citation Analysis]
227 Bhatta P, Whale KD, Sawtell AK, Thompson CL, Rapecki SE, Cook DA, Twomey BM, Mennecozzi M, Starkie LE, Barry EMC, Peters SJ, Kamal AM, Finney HM. Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries. MAbs 2021;13:1859049. [PMID: 33487120 DOI: 10.1080/19420862.2020.1859049] [Reference Citation Analysis]
228 Paris J, Morgan TE, Marzullo BP, Wootton CA, Barrow MP, O'Hara J, O'Connor PB. Two-Dimensional Mass Spectrometry Analysis of IgG1 Antibodies. J Am Soc Mass Spectrom 2021;32:1716-24. [PMID: 34152763 DOI: 10.1021/jasms.1c00096] [Reference Citation Analysis]
229 Spuntarelli V, Negro A, Luciani M, Bentivegna E, Martelletti P. Eptinezumab for the treatment of migraine. Expert Opin Biol Ther 2021;21:999-1011. [PMID: 34009094 DOI: 10.1080/14712598.2021.1931678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 [DOI: 10.1101/2020.04.14.040949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Megha KB, Mohanan PV. Role of immunoglobulin and antibodies in disease management. Int J Biol Macromol 2021;169:28-38. [PMID: 33340621 DOI: 10.1016/j.ijbiomac.2020.12.073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
232 Fernández-Quintero ML, Kroell KB, Bacher LM, Loeffler JR, Quoika PK, Georges G, Bujotzek A, Kettenberger H, Liedl KR. Germline-Dependent Antibody Paratope States and Pairing Specific VH-VL Interface Dynamics. Front Immunol 2021;12:675655. [PMID: 34447370 DOI: 10.3389/fimmu.2021.675655] [Reference Citation Analysis]
233 Bayón-Calderón F, Toribio ML, González-García S. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci 2020;21:E7685. [PMID: 33081391 DOI: 10.3390/ijms21207685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
234 Hou Q, Stringer B, Waury K, Capel H, Haydarlou R, Xue F, Abeln S, Heringa J, Feenstra KA. SeRenDIP-CE: Sequence-based Interface Prediction for Conformational Epitopes. Bioinformatics 2021:btab321. [PMID: 33974039 DOI: 10.1093/bioinformatics/btab321] [Reference Citation Analysis]
235 Imura Y, Tagawa T, Miyamoto Y, Nonoyama S, Sumichika H, Fujino Y, Yamanouchi M, Miki H. Washing with alkaline solutions in protein A purification improves physicochemical properties of monoclonal antibodies. Sci Rep 2021;11:1827. [PMID: 33469121 DOI: 10.1038/s41598-021-81366-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
236 Yanaka S, Nishiguchi S, Yogo R, Watanabe H, Shen J, Yagi H, Uchihashi T, Kato K. Quantitative Visualization of the Interaction between Complement Component C1 and Immunoglobulin G: The Effect of CH1 Domain Deletion. Int J Mol Sci 2022;23:2090. [PMID: 35216207 DOI: 10.3390/ijms23042090] [Reference Citation Analysis]
237 Zhang W, Li R, Jia F, Hu Z, Li Q, Wei Z. A microfluidic chip for screening high-producing hybridomas at single cell level. Lab Chip 2020;20:4043-51. [DOI: 10.1039/d0lc00847h] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
238 D'Angelo A, Chapman R, Sirico M, Sobhani N, Catalano M, Mini E, Roviello G. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemother Pharmacol 2022. [PMID: 35953604 DOI: 10.1007/s00280-022-04459-7] [Reference Citation Analysis]
239 Gupta P, Makowski EK, Kumar S, Zhang Y, Scheer JM, Tessier PM. Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties. Mol Pharm 2022. [PMID: 35108018 DOI: 10.1021/acs.molpharmaceut.1c00373] [Reference Citation Analysis]
240 Tokunaga Y, Takeuchi K. Role of NMR in High Ordered Structure Characterization of Monoclonal Antibodies. Int J Mol Sci 2020;22:E46. [PMID: 33375207 DOI: 10.3390/ijms22010046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
241 Harth S, Frisch C. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development. Methods Mol Biol 2021;2261:291-306. [PMID: 33420997 DOI: 10.1007/978-1-0716-1186-9_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]